Recurrent Genital Herpes After Episodic Antiviral Therapy — What to Do Next (Not Pregnant, Not Living With HIV)
This protocol applies to adults with recurrent genital herpes who are not pregnant and not living with HIV, where episodic antiviral therapy has not provided sufficient recurrence control.
Clinical Scenario
The patient has recurrent genital herpes. They are not pregnant and not living with HIV. The frequency or burden of recurrences is the central clinical concern requiring a change in management strategy.
Previous Treatment and Its Limitation
The standard first-line strategy is episodic short-course oral antiviral therapy, started within 24 hours of symptom onset. The goal of this approach is a reduction in the duration of each individual recurrence by a median of 1–2 days.
When that benefit is insufficient, or when the overall recurrence burden remains the patient’s primary concern, clinical guidelines support advancing to the next step.
Next-Step Treatment Approach
The evidence-based next step is a continuous suppressive antiviral regimen. The choice between available agents is guided by the patient’s annual recurrence frequency. Full regimen details are in the structured protocol below.
Treatment Goal
The primary target is a substantial reduction in recurrence frequency. Patients on suppressive therapy are highly likely to achieve this outcome.
References
DOI: 10.1111/jdv.20450
- Oral aciclovir, valaciclovir and famciclovir are effective at reducing the duration and severity of recurrent genital herpes.
- Aciclovir 400 mg twice daily (for all frequencies of disease recurrence).
- Valaciclovir 500 mg daily (if fewer than 10 recurrences per annum).
- Valaciclovir 1 g daily (if more than 10 recurrences per annum).
- All patients are highly likely to experience a substantial reduction in recurrence frequency on suppressive antiviral therapy.